|
Gliomas
|
|
|
|
M. A. Badruddoja, D. A. Reardon, G.
Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J.
J. Vredenburgh, D. D. Bigner
Phase II trial of iodine 131-labeled murine
anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection
cavity in the treatment of patients with recurrent malignant brain tumors
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1569
|
|
|
K. Jin Kim,
Lihong Wang, Yi-Chi Su,
G. Yancey Gillespie,
Amandeep Salhotra, Bachchu
Lal and John Laterra
Systemic Anti–Hepatocyte Growth
Factor Monoclonal Antibody Therapy Induces the Regression of Intracranial
Glioma Xenografts
Clinical Cancer Research, Vol. 12, 1292-1298, 15 February 2006
 Abstract
| BrainLife |
|
|
J. J. Vredenburgh, D.
Reardon, G. Akabani, A. Friedman, H.
Friedman, R. McLendon, J. Quinn, J.
Rich, M. Zalutsky and D. Bigner
Results of a
phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal
antibody 81C6 (m81C6) administered to deliver a targeted radiation boost
dose of 44 Gy to the surgically created cystic resection cavity perimeter
in the treatment of patients with newly diagnosed primary and metastatic
brain tumors
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1510
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1510
|
|
|
Glioblastoma
|
|
|
|
Chakravarti A, Loeffler JS, Dyson NJ
Insulin-like growth factor receptor I mediates
resistance to anti-epidermal growth factor receptor therapy in primary human
glioblastoma cells through continued activation of phosphoinositide 3-kinase
signaling
Cancer Res 2002 Jan 1;62(1):200-7
|
|
Mischel PS, Cloughesy TF
Targeted
molecular therapy of GBM
Brain Pathol. 2003
Jan;13(1):52-61
|
|
|
Reardon DA, Zalutsky MR, Akabani G, Coleman RE,
Friedman AH, Herndon Ii JE, McLendon RE, Pegram CN, Quinn JA, Rich JN,
Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM,
Wong TZ, Zhao XG, Friedman HS, Bigner DD
A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a
44-Gy resection cavity boost
Neuro Oncol. 2008 Feb 20; [Epub ahead of print]
Abstract |
DBLinks | BL 7:5
|
|
|
Malignant
Lymphoma
|
|
|
|
F. G. El Kamar, L. M.
Deangelis, J. Yahalom, D. D. Correa, B. W. Grant, R. V. Larocca, J. J.
Raizer, D. Schiff, L. E. Abrey
Combined immunochemotherapy with reduced dose
whole brain radiotherapy (WBRT) for newly diagnosed patients with primary
CNS lymphoma (PCNSL)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1518
|
|
H. Schulz, H. Pels, U.
Schlegel, U. Zeelen, U. Germing, A. Engert
Intraventricular application of rituximab as a
treatment option in patients with CNS lymphoma and leptomeningeal disease
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1521
|
|
A.
Torres-Trejo, J. L. Mabold, F. S. Lieberman, S. C. Schold
Rituximab as an alternative treatment for
primary central nervous system lymphoma (PCNSL)
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 490
|
|
|
Metastatic
Tumors
|
|
|
|
Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH,
Friedman HS, Bigner DD, Sampson JH
Efficacy of intracerebral microinfusion of trastuzumab in an
athymic rat model of intracerebral metastatic breast cancer
Clin Cancer Res. 2003 Nov 15;9(15):5514-20.
(PDF Full Text)
|
|
|
A. M. Scott, S. S. Gill, F. Lee, Z. Liu, E. Skrinos, C. Murone, T.
Saunder, B. Chappell, A. Papenfuss, L. J. Old
A Phase I single dose escalation trial of ch806 in patients with advanced
tumors expressing the 806 antigen
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 13028
 Meeting
Abstract
|
News
|
|
|
Neuroblastoma
|
|
|
|
A. L. Yu, A. Batova, R.
Gribi, M. Diccianni, L. Bridgeman, D. Geske, W. London, A. Gilman, F.
Ozkaynak
Antibody-dependent cellular cytotoxicity (ADCC) in
COG ANBL0032: A phase III randomized trial of chimeric anti-GD2 and
GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and
autologous stem cell transplant (ASCT)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2582
|
|
|
Non-Nervous
System Tumors
|
|
|
|
Baselga
J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT,
Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L
Phase II study
of weekly intravenous trastuzumab (Herceptin) in patients with
HER2/neu-overexpressing metastatic breast cancer
Semin
Oncol 1999 Aug;26(4 Suppl 12):78-83
|
|
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM,
Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ
Phase II study of receptor-enhanced chemosensitivity
using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin
in patients with HER2/neu-overexpressing metastatic breast cancer refractory to
chemotherapy treatment
J Clin Oncol 1998 Aug;16(8):2659-71
|
|
Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A,
Dallaire BK
Overview
of the clinical development of rituximab: first monoclonal antibody approved for
the treatment of lymphoma
Semin
Oncol 1999 Oct;26(5 Suppl 14):66-73
|
|
Udo Vanhoefer,
Mitra Tewes, Federico Rojo, Olaf Dirsch,
Norbert Schleucher, Oliver Rosen, Joachim
Tillner, Andreas Kovar, Ada H. Braun, Tanja
Trarbach, Siegfried Seeber, Andreas Harstrick,
José Baselga
Phase
I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal
Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the
Epidermal Growth Factor Receptor
Journal of Clinical Oncology, Vol 22, No 1 (January 1), 2004: pp. 175-184
|
|
